CancerDrs

Lung Cancer clinical trials in Maryland

55 actively recruiting lung cancer trials at 26 sites across Maryland.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Maryland:
  • Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Maryland:
  • Walter Reed National Military Medical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Maryland:
  • Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • TidalHealth Richard A Henson Cancer Institute — Ocean Pines, Maryland
  • TidalHealth Peninsula Regional — Salisbury, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Maryland:
  • Maryland Oncology Hematology, P.A. — Annapolis, Maryland
  • Maryland Oncology Hematology, P.A. — Bethesda, Maryland
  • Maryland Oncology Hematology, P.A. — Brandywine, Maryland
  • Maryland Oncology Hematology - Columbia — Columbia, Maryland
  • Maryland Oncology Hematology, P.A. — Germantown, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Maryland:
  • Local Institution - 0505 — Annapolis, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Maryland:
  • Research Site — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Maryland:
  • American Oncology Partners, PA - The Center for Cancer and Blood Disorders — Bethesda, Maryland
  • Maryland Oncology Hematology — Silver Spring, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…

Sponsor: BioNTech SE
NCT ID: NCT06712355
Sites in Maryland:
  • Frederick Health Hospital- James M Stockman Cancer Institute — Frederick, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …

Sponsor: Bayer
NCT ID: NCT06452277
Sites in Maryland:
  • UM Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Maryland:
  • USOR Maryland Oncology Hematology — Rockville, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Maryland:
  • University of Maryland — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Maryland:
  • Sunstone Therapies, PC — Rockville, Maryland
  • Sheppard Pratt — Towson, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Maryland:
  • University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side e…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07154290
Sites in Maryland:
  • University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carbop…

Sponsor: PrECOG, LLC.
NCT ID: NCT07057791
Sites in Maryland:
  • University of Maryland — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG perform…

Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06745882
Sites in Maryland:
  • University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • Medstar Franklin Square — Baltimore, Maryland
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
  • TidalHealth Peninsula Regional — Salisbury, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertini…

Sponsor: Genprex, Inc.
NCT ID: NCT04486833
Sites in Maryland:
  • Maryland Oncology Hematology — Rockville, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumo…

Sponsor: Molecular Partners AG
NCT ID: NCT07278479
Sites in Maryland:
  • United Theranostics — Glen Burnie, Maryland
View on ClinicalTrials.gov →

Showing 25 of 55 trials with sites in Maryland. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09